An HBC-vectored peptide-based cytomegalovirus vaccine

描述（由申请人提供）：人巨细胞病毒（CMV）是美国出生缺陷的主要感染原因。最近证明，糖蛋白B（gB）/MF 59疫苗在保护妇女免受原发性CMV感染方面具有50%的功效，这是CMV疫苗研究中的一个里程碑。然而，50%的效力可能不足以获得疫苗许可。因此，挑战在于确定可以将什么添加到基于gB的疫苗中以将效力提高到可接受的水平。PI实验室最近的工作表明，CMV血清阳性的人具有高水平的抗体，可以中和病毒进入上皮细胞，而gB/MF 59疫苗无法达到类似的水平。上皮进入特异性中和表位位于由gH、gL、UL 128、UL 130和UL 131（gH/gL/UL 128 -131）组成的病毒粒子糖蛋白复合物内。研究人员的实验室最近确定了两个肽表位，一个来自UL 130，一个来自UL 131，能够引发有效的上皮细胞进入特异性中和反应。co-PI开发了一种新的平台，用于引发对肽表位的抗体应答。将所需肽工程化到肝炎病毒B核心抗原（HBcAg）蛋白的外环中。修饰的蛋白质自组装成病毒样颗粒（VLP），其充当有效的免疫原并引发对插入的肽表位的强烈抗体应答。我们建议设计含有UL 130和UL 131肽表位的嵌合HBcAg蛋白，并评估嵌合VLP在小鼠中引发上皮进入特异性中和活性的能力。将进一步评价最佳嵌合VLP与gB亚单位疫苗的相容性。拟议研究的结果可能为临床开发提供一种新的疫苗策略。

DESCRIPTION (provided by applicant): Human cytomegalovirus (CMV) is the major infectious cause of birth defects in the United States. Recent demonstration that the glycoprotein B (gB)/MF59 vaccine has 50% efficacy in protecting women against primary CMV infection is a landmark in CMV vaccine research. However, 50% efficacy may be insufficient for vaccine licensure. Thus, the challenge is to determine what can be added to a gB-based vaccine to increase efficacy to an acceptable level. Recent work from the PI's laboratory showed that CMV seropositive people have high levels of antibodies that neutralize viral entry into epithelial cells and that comparable levels are not achieved by the gB/MF59 vaccine. Epithelial entry-specific neutralizing epitopes reside within a virion glycoprotein complex consisting of gH, gL, UL128, UL130, and UL131 (gH/gL/UL128-131). The investigator's laboratory recently identified two peptide epitopes, one from UL130 and one from UL131, that are capable of eliciting potent epithelial entry-specific neutralizing responses. The co-PI has developed a novel platform for eliciting antibody responses to peptide epitopes. The desired peptides are engineered into an external loop of the hepatitis virus B core antigen (HBcAg) protein. The modified proteins self- assemble into virus-like particles (VLPs), which serve as potent immunogens and elicit strong antibody responses to the inserted peptide epitopes. We propose to engineer chimeric HBcAg proteins that contain the UL130 and UL131 peptide epitopes and evaluate the chimeric VLPs for their ability to elicit epithelial entry- specific neutralizing activities in mice. Optimal chimeric VLPs will be further evaluated for compatibility with the gB subunit vaccine. The results of the proposed studies may provide a novel vaccine strategy for advancement to clinical development.